Circulating Micrornas Predict Survival of Patients with Tumors of Glial Origin

A. Drusco, P. Fadda, G. Nigita, M. Fassan, A. Bottoni, Gardiman MP, D. Sacchi, F. Calore, M. Carosi, A. Antenucci, B. Casini, H. Kelani, E. Pescarmona, Di Leva G, N. Zanesi, Berger MS, Croce CM

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The World Health Organization has recently introduced molecular prognostic-diagnostic biomarkers in the classification of Central Nervous System (CNS) tumors. In order to characterize subclasses of tumors that cannot find a precise location in the current classification, and, or cannot be tested because of scant material, it is important to find new molecular biomarkers in tissue and, or biological fluid samples. In this study, we identified serum microRNAs that could serve as biomarkers for the diagnosis and prognosis of patients with tumors of glial origin. We retrospectively analyzed microRNA expression in the serum extracellular vesicles of patients with tumors of glial origin. Extracellular vesicles RNA was analyzed by Nanostring. qRT-PCR confirmed 6 overexpressed microRNAs: hsa-miR-4443, hsa-miR-422a, hsa-miR-494-3p, hsa-miR-502-5p, hsa-miR-520f-3p, and hsa-miR-549a. Hsa-miR-4443 was the only microRNA that showed significant differences in most comparisons. In situ hybridization (ISH), confirmed that our signature was mostly expressed in cancer cells. Importantly, hsa-miR-549a and hsa-miR-502-5p expression predicted prognosis in patients with tumors of glial origin. Although more studies are needed, we demonstrated that serum vesicles microRNA profiles are promising diagnostic and prognostic molecular biomarkers that will find an actual application in the clinical practice of CNS tumors.

Original languageEnglish
Pages (from-to)105-112
Number of pages8
JournalEBioMedicine
Volume30
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

MicroRNAs
Neuroglia
Tumors
Biomarkers
Survival
Central Nervous System Neoplasms
Molecular Pathology
Neoplasms
Neurology
Serum
In Situ Hybridization
RNA
Polymerase Chain Reaction
Cells
Health
Tissue
Fluids
Extracellular Vesicles
human MIRN502 microRNA

Keywords

  • Biomarkers
  • CNS tumors
  • Diagnosis
  • microRNA
  • Prognosis
  • Serum

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Drusco, A., Fadda, P., Nigita, G., Fassan, M., Bottoni, A., MP, G., ... CM, C. (2018). Circulating Micrornas Predict Survival of Patients with Tumors of Glial Origin. EBioMedicine, 30, 105-112. https://doi.org/10.1016/j.ebiom.2018.03.022

Circulating Micrornas Predict Survival of Patients with Tumors of Glial Origin. / Drusco, A.; Fadda, P.; Nigita, G.; Fassan, M.; Bottoni, A.; MP, Gardiman; Sacchi, D.; Calore, F.; Carosi, M.; Antenucci, A.; Casini, B.; Kelani, H.; Pescarmona, E.; G, Di Leva; Zanesi, N.; MS, Berger; CM, Croce.

In: EBioMedicine, Vol. 30, 01.04.2018, p. 105-112.

Research output: Contribution to journalArticle

Drusco, A, Fadda, P, Nigita, G, Fassan, M, Bottoni, A, MP, G, Sacchi, D, Calore, F, Carosi, M, Antenucci, A, Casini, B, Kelani, H, Pescarmona, E, G, DL, Zanesi, N, MS, B & CM, C 2018, 'Circulating Micrornas Predict Survival of Patients with Tumors of Glial Origin', EBioMedicine, vol. 30, pp. 105-112. https://doi.org/10.1016/j.ebiom.2018.03.022
Drusco A, Fadda P, Nigita G, Fassan M, Bottoni A, MP G et al. Circulating Micrornas Predict Survival of Patients with Tumors of Glial Origin. EBioMedicine. 2018 Apr 1;30:105-112. https://doi.org/10.1016/j.ebiom.2018.03.022
Drusco, A. ; Fadda, P. ; Nigita, G. ; Fassan, M. ; Bottoni, A. ; MP, Gardiman ; Sacchi, D. ; Calore, F. ; Carosi, M. ; Antenucci, A. ; Casini, B. ; Kelani, H. ; Pescarmona, E. ; G, Di Leva ; Zanesi, N. ; MS, Berger ; CM, Croce. / Circulating Micrornas Predict Survival of Patients with Tumors of Glial Origin. In: EBioMedicine. 2018 ; Vol. 30. pp. 105-112.
@article{abd83f9a1a514829963feda8819f18a7,
title = "Circulating Micrornas Predict Survival of Patients with Tumors of Glial Origin",
abstract = "The World Health Organization has recently introduced molecular prognostic-diagnostic biomarkers in the classification of Central Nervous System (CNS) tumors. In order to characterize subclasses of tumors that cannot find a precise location in the current classification, and, or cannot be tested because of scant material, it is important to find new molecular biomarkers in tissue and, or biological fluid samples. In this study, we identified serum microRNAs that could serve as biomarkers for the diagnosis and prognosis of patients with tumors of glial origin. We retrospectively analyzed microRNA expression in the serum extracellular vesicles of patients with tumors of glial origin. Extracellular vesicles RNA was analyzed by Nanostring. qRT-PCR confirmed 6 overexpressed microRNAs: hsa-miR-4443, hsa-miR-422a, hsa-miR-494-3p, hsa-miR-502-5p, hsa-miR-520f-3p, and hsa-miR-549a. Hsa-miR-4443 was the only microRNA that showed significant differences in most comparisons. In situ hybridization (ISH), confirmed that our signature was mostly expressed in cancer cells. Importantly, hsa-miR-549a and hsa-miR-502-5p expression predicted prognosis in patients with tumors of glial origin. Although more studies are needed, we demonstrated that serum vesicles microRNA profiles are promising diagnostic and prognostic molecular biomarkers that will find an actual application in the clinical practice of CNS tumors.",
keywords = "Biomarkers, CNS tumors, Diagnosis, microRNA, Prognosis, Serum",
author = "A. Drusco and P. Fadda and G. Nigita and M. Fassan and A. Bottoni and Gardiman MP and D. Sacchi and F. Calore and M. Carosi and A. Antenucci and B. Casini and H. Kelani and E. Pescarmona and G, {Di Leva} and N. Zanesi and Berger MS and Croce CM",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.ebiom.2018.03.022",
language = "English",
volume = "30",
pages = "105--112",
journal = "EBioMedicine",
issn = "2352-3964",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Circulating Micrornas Predict Survival of Patients with Tumors of Glial Origin

AU - Drusco, A.

AU - Fadda, P.

AU - Nigita, G.

AU - Fassan, M.

AU - Bottoni, A.

AU - MP, Gardiman

AU - Sacchi, D.

AU - Calore, F.

AU - Carosi, M.

AU - Antenucci, A.

AU - Casini, B.

AU - Kelani, H.

AU - Pescarmona, E.

AU - G, Di Leva

AU - Zanesi, N.

AU - MS, Berger

AU - CM, Croce

PY - 2018/4/1

Y1 - 2018/4/1

N2 - The World Health Organization has recently introduced molecular prognostic-diagnostic biomarkers in the classification of Central Nervous System (CNS) tumors. In order to characterize subclasses of tumors that cannot find a precise location in the current classification, and, or cannot be tested because of scant material, it is important to find new molecular biomarkers in tissue and, or biological fluid samples. In this study, we identified serum microRNAs that could serve as biomarkers for the diagnosis and prognosis of patients with tumors of glial origin. We retrospectively analyzed microRNA expression in the serum extracellular vesicles of patients with tumors of glial origin. Extracellular vesicles RNA was analyzed by Nanostring. qRT-PCR confirmed 6 overexpressed microRNAs: hsa-miR-4443, hsa-miR-422a, hsa-miR-494-3p, hsa-miR-502-5p, hsa-miR-520f-3p, and hsa-miR-549a. Hsa-miR-4443 was the only microRNA that showed significant differences in most comparisons. In situ hybridization (ISH), confirmed that our signature was mostly expressed in cancer cells. Importantly, hsa-miR-549a and hsa-miR-502-5p expression predicted prognosis in patients with tumors of glial origin. Although more studies are needed, we demonstrated that serum vesicles microRNA profiles are promising diagnostic and prognostic molecular biomarkers that will find an actual application in the clinical practice of CNS tumors.

AB - The World Health Organization has recently introduced molecular prognostic-diagnostic biomarkers in the classification of Central Nervous System (CNS) tumors. In order to characterize subclasses of tumors that cannot find a precise location in the current classification, and, or cannot be tested because of scant material, it is important to find new molecular biomarkers in tissue and, or biological fluid samples. In this study, we identified serum microRNAs that could serve as biomarkers for the diagnosis and prognosis of patients with tumors of glial origin. We retrospectively analyzed microRNA expression in the serum extracellular vesicles of patients with tumors of glial origin. Extracellular vesicles RNA was analyzed by Nanostring. qRT-PCR confirmed 6 overexpressed microRNAs: hsa-miR-4443, hsa-miR-422a, hsa-miR-494-3p, hsa-miR-502-5p, hsa-miR-520f-3p, and hsa-miR-549a. Hsa-miR-4443 was the only microRNA that showed significant differences in most comparisons. In situ hybridization (ISH), confirmed that our signature was mostly expressed in cancer cells. Importantly, hsa-miR-549a and hsa-miR-502-5p expression predicted prognosis in patients with tumors of glial origin. Although more studies are needed, we demonstrated that serum vesicles microRNA profiles are promising diagnostic and prognostic molecular biomarkers that will find an actual application in the clinical practice of CNS tumors.

KW - Biomarkers

KW - CNS tumors

KW - Diagnosis

KW - microRNA

KW - Prognosis

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=85045284056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045284056&partnerID=8YFLogxK

U2 - 10.1016/j.ebiom.2018.03.022

DO - 10.1016/j.ebiom.2018.03.022

M3 - Article

AN - SCOPUS:85045284056

VL - 30

SP - 105

EP - 112

JO - EBioMedicine

JF - EBioMedicine

SN - 2352-3964

ER -